Expiration date: 06/2025
The composition and form of issue:
Eye drops 1 ml
cytochrome C 0, 675 mg
adenosine 2 mg
nicotinamide 20 mg
excipients: benzalkonium chloride-0, 04 mg sodium succinate hexahydrate sodium sorbitol phosphate disubstituted 2-water sodium phosphate monosubstituted 2-water water for injection
in plastic dropper bottles of 10 ml in a box 1 bottle.
Description of dosage form:
Transparent solution of red color.
Characteristic:
Combined drug that improves the energy metabolism of the lens, stimulator of tissue regeneration.
Pharmacokinetics:
When applied topically, cytochrome C is not absorbed into the blood, the body is metabolized completely. In the destruction of cytochrome C, the same metabolic pathways are involved as in the destruction of amino acids, and heme is cleaved (biotransformed) to bilirubin, which is excreted with bile. Adenosine freely passes into the cornea and spreads to all tissues T1 / 2 adenosine from plasma is less than one minute, metabolized in almost all tissues with the formation of inosine, xanthine and urate, freely excreted in the urine. Ribose is metabolized to glyceraldehyde-3-phosphate, then to pyruvate and burned in the Krebs cycle. Nicotinamide is rapidly absorbed and partially metabolized to nicotinic acid. Both of these compounds are converted to N-methylnicotinamide, which is further broken down in the liver. Metabolites and unmodified nicotinamide are excreted in the urine.
Description of pharmacological action:
Cytochrome C plays an important role in the biochemical process of oxidation reduction in the tissues of the eyeball. Sodium succinate is an activator of cell metabolism and respiration. Adenosine, a precursor of ATP, is involved in metabolic reactions of the lens. Nicotinamide stimulates the synthesis of nicotinamide adenine nucleotide (NAD), a cofactor of dehydrogenases.
Indications:
Cataracts of various origin, prevention of cataract development.
Contraindications:
Individual hypersensitivity to the components of the drug.
Use during pregnancy and lactation:
There is no sufficient experience in the use of the drug during pregnancy, breastfeeding and in children. It may be used for the treatment of pregnant and lactating mothers as prescribed by the attending physician, if the expected therapeutic effect exceeds the risk of possible side effects.
Side effect:
Local: short-term burning and tingling of the eyes. Allergic reaction from the conjunctiva, contact dermatitis.
Systemic effects are extremely rare. Nausea, hypotension, dizziness and shortness of breath (short-term). Nicotinic acid has a vasodilating effect and can cause hot flashes, a feeling of heat, fainting and a feeling of pulsation in the temples.
Drug interaction:
There were no clinically significant interactions with other drugs.
Dosage and administration:
Conjunctival. 1-2 drops in the conjunctival SAC, 3 times a day.
Overdose:
There is no data on drug overdose.
Precautionary measures:
It is possible to use for the treatment of children as prescribed by the attending physician, if the expected therapeutic effect exceeds the risk of possible side effects.
If the patient wears soft contact lenses, then he should not use the drug, because the preservative can be deposited in soft contact lenses and have an adverse effect on the tissues of the eye.
Contact lenses before instilling the drug should be removed and re-installed after 15 minutes.
Special instruction:
Shelf life after opening the bottle 1 month.
